Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAMI/ANSI Human Factors Revised Guideline Will Soon Be Ready For Use

This article was originally published in The Gray Sheet

Executive Summary

The Association for the Advancement of Medical Instrumentation and the American National Standards Institute expect to publish revised guidelines on human factors design processes for medical devices by the summer of 2001.

You may also be interested in...



FDA Letter Spells End Of Recall For Ethicon's Endopouch Pro

FDA has informed Ethicon in a Sept. 18 letter that its concerns regarding a 1999 field action for the firm's Endopouch Pro specimen retrieval bag are largely resolved, according to the J&J subsidiary.

Risk management

Final FDA guidance entitled "Medical Device Use - Safety: Incorporating Human Factors Engineering Into Risk Management" is issued July 18. Validation of a device with realistic users is always necessary at the design process, guidance states, but may not need to be extensive "if small scale iterative testing of interface components is done adequately as the device was developed"

FDA Device Reviews Need Stronger Patient Safety Criteria - IoM Report

FDA's Center for Devices and Radiological Health should place greater emphasis on patient safety in actual use and real-life settings when approving medical devices, the Institute of Medicine concludes in a report on medical errors, "To Err is Human," released Nov. 30.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel